.jpg?format=webp&width=780)
Acute leukaemias often harbour KMT2A rearrangements or NMP1 mutations, which drive menin-mediated chromatin remodelling and are associated with a poor prognosis. Now, a first-in-human phase I trial has revealed the promising safety and efficacy of the menin–KMT2A interaction inhibitor revumenib in this context.
Like
Save
Share